On Tuesday, September 15, 2015, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) supported, by a vote of Yes-11 to No-1, with one abstention, the efficacy of Seasonal Trivalent Influenza Vaccine, Surface Antigen, Inactivated, Adjuvanted with MF59 (FLUAD) manufactured by Novartis. The VRBPAC also supported its safety, by a vote of 10-Yes to 2-No, with one abstention.
Back to All Events
Earlier Event: September 11Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Committee
Later Event: September 15Science Board to the FDA